יחס מחיר לרווח Fulgent (FLGT)
Fulgent Genetics, Inc. (FLGT) is developing a high-tech genetic analysis environment, attracting IT specialists with innovative software. The current P/E of the business, as shown on this GURU.Markets chart, remains around -7.80. However, reagent shortages and geopolitics are hindering international testing. The situation is further complicated by strict FDA oversight and a decline in demand following the COVID boom, despite loyalty from clinics.
פילוחים אנליטיים של חברת Fulgent Genetics, Inc.
When assessing the margin of safety for Fulgent Genetics, Inc. (FLGT), it is essential to understand that the P/E ratio measures the payback period of the business's market value based on generated net income. By analyzing the P/E ratio trends of Fulgent Genetics, Inc. (FLGT), an investor can identify asset overvaluation, which becomes critical during supply chain disruptions of imported reagents or IT components that limit the operational growth of diagnostics.
